Akari Therapeutics Hires Vatnak Vat-Ho as Chief Business Officer
Tampa, FL and London – October 29, 2026 -- Akari Therapeutics (Nasdaq: AKTX) has appointed Vatnak Vat-Ho as Chief Business Officer, adding an executive who has held senior roles in oncology transactions totaling more than $25 billion in aggregate value.
Vat-Ho will run corporate strategy, partnering, licensing and investor engagement
Vat-Ho will lead corporate and business development at the oncology biotech, which is developing antibody drug conjugates (ADCs) built on a novel RNA splicing-disrupting payload called PH1. His remit covers corporate strategy, partnering and licensing, and investor engagement as the company advances its lead TROP2-targeted ADC, AKTX-101, toward the clinic.
He brings more than 20 years of experience across oncology business development, biopharmaceutical strategy, equity research and healthcare investing. His transaction record involves Pfizer, Exelixis, BioNTech, Merck KGaA, Roivant and Roche/Genentech.